Caseware UK (AP4) 2023.0.135 2023.0.135 2023-11-302023-11-302false2truetrueNo description of principal activityThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2022-12-01false 01830865 2022-12-01 2023-11-30 01830865 2021-12-01 2022-11-30 01830865 2023-11-30 01830865 2022-11-30 01830865 c:Director1 2022-12-01 2023-11-30 01830865 d:CurrentFinancialInstruments 2023-11-30 01830865 d:CurrentFinancialInstruments 2022-11-30 01830865 d:CurrentFinancialInstruments d:WithinOneYear 2023-11-30 01830865 d:CurrentFinancialInstruments d:WithinOneYear 2022-11-30 01830865 d:ShareCapital 2023-11-30 01830865 d:ShareCapital 2022-11-30 01830865 d:RetainedEarningsAccumulatedLosses 2023-11-30 01830865 d:RetainedEarningsAccumulatedLosses 2022-11-30 01830865 c:FRS102 2022-12-01 2023-11-30 01830865 c:AuditExempt-NoAccountantsReport 2022-12-01 2023-11-30 01830865 c:FullAccounts 2022-12-01 2023-11-30 01830865 c:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 01830865 2 2022-12-01 2023-11-30 01830865 e:PoundSterling 2022-12-01 2023-11-30 iso4217:GBP xbrli:pure

Registered number: 01830865









BIOTECH LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 NOVEMBER 2023

 
BIOTECH LIMITED
REGISTERED NUMBER: 01830865

BALANCE SHEET
AS AT 30 NOVEMBER 2023

2023
2023
2022
2022
Note
£
£
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
131,844
148,596

Cash at bank and in hand
 5 
127
126

  
131,971
148,722

Creditors: amounts falling due within one year
 6 
(759)
(16,713)

Net current assets
  
 
 
131,212
 
 
132,009

Total assets less current liabilities
  
131,212
132,009

  

Net assets
  
131,212
132,009


Capital and reserves
  

Called up share capital 
  
10,000
10,000

Profit and loss account
  
121,212
122,009

Total equity
  
131,212
132,009


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




H Vaghela
Director

Date: 29 August 2024

Page 1

 
BIOTECH LIMITED
REGISTERED NUMBER: 01830865
    
BALANCE SHEET (CONTINUED)
AS AT 30 NOVEMBER 2023

The notes on pages 3 to 5 form part of these financial statements.

Page 2

 
BIOTECH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

1.


General information

Biotech Limited is a private company, limited by shares. The company is incorporated in England and Wales and the address of the registered office is 96 Camden Road, London, NW1 9EA.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 3

 
BIOTECH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

2.Accounting policies (continued)

 
2.7

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

 
2.8

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees




The average monthly number of employees, including directors, during the year was 2 (2022 - 2).

Page 4

 
BIOTECH LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

4.


Debtors

2023
2022
£
£


Other debtors
131,844
148,596



5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
127
126



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Corporation tax
282
329

Other creditors
27
16,029

Accruals and deferred income
450
355

759
16,713


 
Page 5